admin

Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components.

Bucki R1, Byfield FJ, Kulakowska A, McCormick ME, Drozdowski W, Namiot Z, Hartung T, Janmey PA.October 1, 2008 Abstract The various functions of gelsolin in extracellular compartments are not yet clearly defined but include actin scavenging and antiinflammatory effects. Gelsolin was recently reported to bind endotoxin (LPS) from various Gram-negative bacteria with high affinity. In this study we investigate whether gelsolin also …

Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. Read More »

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman

MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) — BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics’ accolade was based …

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman Read More »

July 1, 2015: BioAegis Therapeutics Collaboration with Harvard School of Public Health Discovers Plasma Gelsolin Boosts the Immune Response to Pathogens

Dr. Lester Kobzik, Professor of Medicine, Harvard T.H. Chan School of Public Health Publishes: Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function. This major plasma gelsolin advancement was published in May in Journal of American Physiology—Lung, Cellular and Molecular Physiology. Read article here.

April 15, 2015: BioAegis Therapeutics Completes Initial $8 Million Convertible Note: Round Oversubscribed

Company Enters into Collaborative Research Agreement with NIAID and Company to Run Phase 2a/b Trials in EU BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that simultaneously modulates inflammation and boosts immune function announced that its recently closed convertible note round was oversubscribed by investors. Read article …

April 15, 2015: BioAegis Therapeutics Completes Initial $8 Million Convertible Note: Round Oversubscribed Read More »